Ysios Capital
Ysios Capital is a leading life sciences investor focused on financing highly innovative biotech companies worldwide. The firm provides resources to develop novel therapies for indications with high unmet medical needs, aiming to have a positive impact on patients and society. With a global outlook and proven performance, Ysios Capital manages over €400 million in assets and has invested in 40 companies, bringing 19 products to market and having over 70 products at the clinical stage.
Ysios Capital
What We Do
Ysios Capital provides financial resources to biotech ventures to develop novel therapies.
The firm offers strategic guidance to its portfolio companies, leveraging its team's scientific, financial, and entrepreneurial expertise.
Ysios Capital provides mentorship to new and promising companies, helping them achieve success.
The firm connects its portfolio companies with a network of industry experts and potential partners.
Geographic Focus
Portfolio
Adcendo is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (ADCs).
#Biotechnology
Anaconda Biomed is among the world’s most innovative early-stage medical technology companies.
#Medical Technology
Aura Biosciences is applying nanotechnology to the fight against cancer with its novel viral nanoparticle technology.
#Biotechnology
BioVex was focused on the development and commercialization of biological treatments for cancer and infectious disease using oncolytic viruses.
#Biotechnology
CorWave is developing next-generation blood pumps for heart failure patients.
#Medical Technology
Cytoki Pharma is engaged in the development of protein drugs for diseases characterized by epithelial injury.
#Biotechnology